Combination of flavonoids from Oroxylum indicum seed extracts and acarbose improves the inhibition of postprandial blood glucose: In vivo and in vitro study - 08/06/17

pages | 9 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Synergistic hypoglycemic effect of OISE and acarbose is investigated in vivo and in vitro. |
• | Combination of either acarbose or miglitol with OISE, a non-competitive inhibitor, synergistically inhibited α-glucosidase. |
• | Baicalein proved to be the major active component of OISE. |
• | Individual OISE or combined with acarbose showed PBG lowering effect in type 1 diabetic and normoglycemic mice. |
Abstract |
The combined effect of Oroxylum indicum seed extracts (OISE) or major flavonoids from OISE and acarbose on reducing postprandial blood glucose (PBG) levels was investigated in vitro and in vivo. In vitro, the IC50 values of OISE and baicalein against α-glucosidase were 43.4±0.731μgmL−1 and 25.9±0.412μgmL−1 respectively. A combination of acarbose with OISE or baicalein synergistically inhibited rat intestinal α-glucosidase. The combination index (CI) values for acarbose with OISE ranged from 0.33 to 0.75, suggesting a synergistic but not additive effect. OISE was determined to be a non-competitive inhibitor of maltose-hydrolyzing activity. In vivo, OISE were administered to normoglycemic and diabetic mice, either alone or in combination with acarbose. At doses between 50 and 200mgkg−1, OISE enhanced the efficacy of acarbose by up to 5-fold. These results demonstrated that OISE enhances the efficacy of acarbose in vivo, and that the combination of OISE and acarbose displayed a synergistic effect in vitro. Therefore, OISE can be used to design dietary supplements to treat diabetes.
Le texte complet de cet article est disponible en PDF.Abbreviations : OISE, AUC, DM, FBG, GLP-1, IGT, PBG, CMC-Na, TCM
Keywords : Oroxylum indicum, Acarbose, Synergism, Postprandial blood glucose, α-Glucosidase, Baicalein
Plan
Vol 91
P. 890-898 - juillet 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?